A multicenter prospective observational study of atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) in patients with unresectable advanced or relapsed EGFR-mutation positive nonsquamous non-small-cell lung cancer: ABCP observational study

A multicenter prospective observational study of atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) in patients with unresectable advanced or relapsed EGFR-mutation positive nonsquamous non-small-cell lung cancer: ABCP observational study - ABCP multicenter prospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037967

Enrollment

140

Registered

2019-09-10

Start date

2019-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, A patient aged 20 or older at the time of informed consent. 2, A patient with unresectable advanced or relapsed EGFR-mutation positive nonsquamous non-small-cell lung cancer.(Eligible regardless of EGFR-mutation subtypes) 3, A patient who has been treated with prior EGFR-TKI therapies.(Eligible if a patient received a prior osimertinib therapy after 1st or 2nd generation EGFR-TKI therapies) 4, A patient who is to receive ABCP therapy in a practical setting based on package inserts and guidelines for optimal use. 5, A patient who provides written informed consent.

Exclusion criteria

Exclusion criteria: A Patient who is judged ineligible to enroll the study by an attending doctor.

Design outcomes

Primary

Measure	Time frame
Progression Free Survival: PFS	—

Secondary

Measure	Time frame
Overall survival: OS Time to treatment failure: TTF Overall response rate: ORR Adverse events Patient reported outcomes: PRO (Assessment of chemotherapy-induced peripheral neuropathy) And others	—

Countries

Japan

Contacts

Public ContactHiroshige Yoshioka

Kansai Medical University Hospital Department of Thoracic Oncology

hgyoshioka@gmail.com072-804-0101

Outcome results